Gene Disease Score gda Association Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 3447
Gene Symbol: IFNA13
IFNA13
CUI: C0019163
Disease: Hepatitis B
Hepatitis B
0.100 Biomarker BEFREE Hepatitis B surface antigen (HBsAg) decline was significantly associated with elevated CD86<sup>+</sup> pDC% (r = 0.348, P = 0.015) during PEG-IFN-α-2a treatment. 29791282

2018

Entrez Id: 3447
Gene Symbol: IFNA13
IFNA13
CUI: C0019163
Disease: Hepatitis B
Hepatitis B
0.100 Biomarker BEFREE IFN-α-mediated Base Excision Repair Pathway Correlates with Antiviral Response Against Hepatitis B Virus Infection. 28983111

2017

Entrez Id: 3447
Gene Symbol: IFNA13
IFNA13
CUI: C0019163
Disease: Hepatitis B
Hepatitis B
0.100 Biomarker BEFREE A one-year course of Peg-IFN has the advantage of providing immune-mediated control of the hepatitis B virus (HBV) infection, the possibility of achieving a sustained off-treatment response in nearly 30% of the patients and ultimately, HBsAg loss in approximately 30%-50% of the latter patients during long-term off treatment follow-up. 29427498

2018

Entrez Id: 3447
Gene Symbol: IFNA13
IFNA13
CUI: C0019163
Disease: Hepatitis B
Hepatitis B
0.100 Biomarker BEFREE A total of 210 patients with chronic hepatitis C genotype 1 of high viral load (baseline serum hepatitis C virus RNA > 5.0 log10 IU/mL) were divided into two groups by type of treatment: triple therapy with telaprevir, pegylated-interferon-α (PEG-IFNα), and ribavirin (RBV) for 24 wk (n = 88), or dual therapy with PEG-IFNα and RBV for 48 wk (n = 122). 25914481

2015

Entrez Id: 3447
Gene Symbol: IFNA13
IFNA13
CUI: C0019163
Disease: Hepatitis B
Hepatitis B
0.100 Biomarker BEFREE A total of 212 hepatitis B e antigen (HBeAg)-positive patients treated with PEG-IFN monotherapy were enrolled in this study. 24517415

2015

Entrez Id: 3447
Gene Symbol: IFNA13
IFNA13
CUI: C0019163
Disease: Hepatitis B
Hepatitis B
0.100 Biomarker BEFREE A total of 257 patients with chronic HBV, treated with PEG-IFN for 48 weeks, were identified from 13 tertiary hospitals included in the hepatitis B database of the Thai Association for the Study of the Liver (THASL). 28635613

2018

Entrez Id: 3447
Gene Symbol: IFNA13
IFNA13
CUI: C0019163
Disease: Hepatitis B
Hepatitis B
0.100 Biomarker BEFREE A total of 30 patients with CHB who achieved HBsAg seroclearance following peg-IFN-α therapy and an additional 30 age-, gender-, hepatitis B e antigen (HBeAg) status- and hepatitis B virus genotype-matched patients with CHB without HBsAg seroclearance following peg-IFN-α therapy, were enrolled as a discovery cohort. 25324041

2015

Entrez Id: 3447
Gene Symbol: IFNA13
IFNA13
CUI: C0019163
Disease: Hepatitis B
Hepatitis B
0.100 GeneticVariation BEFREE A total of 39 single nucleotide polymorphism loci in 23 genes of the TLR-IFN pathway and four HLA polymorphism loci associated with chronic HBV infection identified by GWAS were selected for genotyping. 25469587

2015

Entrez Id: 3447
Gene Symbol: IFNA13
IFNA13
CUI: C0019163
Disease: Hepatitis B
Hepatitis B
0.100 Biomarker BEFREE Although IFN has been used in the treatment of viral hepatitis for more than a decade, the role of IFN-alpha-receptor in HBV infection has not been intensively studied. 19103527

2008

Entrez Id: 3447
Gene Symbol: IFNA13
IFNA13
CUI: C0019163
Disease: Hepatitis B
Hepatitis B
0.100 Biomarker BEFREE Among children with hepatitis B envelope antigen-positive genotype C chronic HBV infection, we compared the efficacy of combination therapy with nucleotide analogues and IFN-α in 11 children with 12 historical cases treated with IFN monotherapy. 29981262

2018

Entrez Id: 3447
Gene Symbol: IFNA13
IFNA13
CUI: C0019163
Disease: Hepatitis B
Hepatitis B
0.100 AlteredExpression BEFREE Based on these results, precore mutants do respond to IFN, and therefore, IFN is indicated in patients with HBeAb, especially those with low serum HBV DNA levels. 8745316

1995

Entrez Id: 3447
Gene Symbol: IFNA13
IFNA13
CUI: C0019163
Disease: Hepatitis B
Hepatitis B
0.100 Biomarker BEFREE Chronic HCV and HBV infection and IFN-based HCV therapy were not associated with DM. 29901821

2018

Entrez Id: 3447
Gene Symbol: IFNA13
IFNA13
CUI: C0019163
Disease: Hepatitis B
Hepatitis B
0.100 Biomarker BEFREE Clearance of Hepatitis B e antigen (HBeAg) was also more frequent in NASVAC group compared to Peg-IFN recipients. 30133478

2018

Entrez Id: 3447
Gene Symbol: IFNA13
IFNA13
CUI: C0019163
Disease: Hepatitis B
Hepatitis B
0.100 Biomarker BEFREE Compared with lower doses and shorter durations, the licensed PEG-IFNα-2a treatment regimen (180 μg/48 weeks) was the most efficacious and beneficial for HBeAg-positive patients predominantly infected with hepatitis B virus genotypes B or C. 22045673

2011

Entrez Id: 3447
Gene Symbol: IFNA13
IFNA13
CUI: C0019163
Disease: Hepatitis B
Hepatitis B
0.100 Biomarker BEFREE Conclusion: These findings highlight a host gene, UBE2L3, contributing to the susceptibility to persistent HBV infection; UBE2L3 may be involved in IFN-mediated viral suppression and serve as a potential target in the prevention and treatment of HBV infection. 30614547

2019

Entrez Id: 3447
Gene Symbol: IFNA13
IFNA13
CUI: C0019163
Disease: Hepatitis B
Hepatitis B
0.100 AlteredExpression BEFREE Defining an "immediate virological response (IVR)" as the loss of serum hepatitis C virus (HCV) RNA 7 d after the first administration of PEG-IFN alpha, we conducted a 12-wk course of PEG-IFN alpha2a monotherapy without the addition of ribavirin for 38 patients who had low pretreatment HCV RNA load and exhibited IVR. 20333792

2010

Entrez Id: 3447
Gene Symbol: IFNA13
IFNA13
CUI: C0019163
Disease: Hepatitis B
Hepatitis B
0.100 Biomarker BEFREE Endogenous HBV-CpG ODNs from the HBV genome induce IFN-α production so that nanoparticle-encapsulated HBV-CpG may act as an HBsAg vaccine adjuvant and may also represent a potent therapeutic agent for the treatment of chronic HBV infection. 23907803

2014

Entrez Id: 3447
Gene Symbol: IFNA13
IFNA13
CUI: C0019163
Disease: Hepatitis B
Hepatitis B
0.100 Biomarker BEFREE Extended treatment with PEG IFNα-2a with lamivudine or adefovir for 96 weeks is a promising strategy to achieve high rates of sustainable HBeAg and HBsAg seroconversion and HBV DNA suppression in patients with HBeAg-positive CHB. 23615131

2013

Entrez Id: 3447
Gene Symbol: IFNA13
IFNA13
CUI: C0019163
Disease: Hepatitis B
Hepatitis B
0.100 GeneticVariation BEFREE For HBeAg-positive patients and HBeAg-negative patients with genotype D infection, PEG-IFN therapy could be terminated early at week 12 or 24 in primary non-responders defined by the Hepatitis B surface antigen stopping rules. 24738850

2014

Entrez Id: 3447
Gene Symbol: IFNA13
IFNA13
CUI: C0019163
Disease: Hepatitis B
Hepatitis B
0.100 Biomarker BEFREE Higher IFN-<i>λ</i>3 concentrations are associated with response to HBV vaccination, self-limited HBV infection, and HCV resolution. 29226133

2017

Entrez Id: 3447
Gene Symbol: IFNA13
IFNA13
CUI: C0019163
Disease: Hepatitis B
Hepatitis B
0.100 AlteredExpression BEFREE His serum hepatitis C virus (HCV) RNA level became undetectable 1 week after the initiation of peg-IFN-alpha2b plus ribavirin treatment. 17287904

2006

Entrez Id: 3447
Gene Symbol: IFNA13
IFNA13
CUI: C0019163
Disease: Hepatitis B
Hepatitis B
0.100 Biomarker BEFREE However, these sustained response rates can be significantly increased by carefully selecting candidates for PEG-IFN therapy based upon baseline ALT and HBV DNA levels, viral genotype and IL28B polymorphisms, by extending PEG-IFN therapy beyond 48 weeks and, most importantly, by applying early on-treatment stopping rules based upon HBsAg kinetics. 23286860

2013

Entrez Id: 3447
Gene Symbol: IFNA13
IFNA13
CUI: C0019163
Disease: Hepatitis B
Hepatitis B
0.100 Biomarker BEFREE Identifying the key negative factors and elucidating the regulating mechanism are essential for improving anti-HBV (hepatitis B virus) efficacy of IFNα. 30723923

2019

Entrez Id: 3447
Gene Symbol: IFNA13
IFNA13
CUI: C0019163
Disease: Hepatitis B
Hepatitis B
0.100 Biomarker BEFREE Impaired expression and function of TLR8 in chronic HBV infection and its association with treatment responses during peg-IFN-α-2a antiviral therapy. 28236535

2017

Entrez Id: 3447
Gene Symbol: IFNA13
IFNA13
CUI: C0019163
Disease: Hepatitis B
Hepatitis B
0.100 Biomarker BEFREE In conclusion, a 24-month course of treatment with 6 MU IFN-alpha2b was well tolerated by most patients, led to sustained suppression of HBV in one third, and attenuated hepatitis in 81% of patients. 9398007

1997